New Delhi (JNN). Many countries of the world have approved the vaccine for children. However, most of these countries have approved the vaccine for children above the age of 12 years. At the same time, there are only a few countries that have approved the vaccine for children younger than this. In India too, preparations are going on for the vaccine for children in the age group of 2-18 years. According to an estimate, the number of children in the age group of 2-18 years in the country is more than 350 million. It is also believed that if all goes well, its dose can be given in the next five months.

SEC approves Covaccine

Talking about India, the Subject Expert Committee (SEC) has allowed Covaccine to be used as an emergency for children aged 2-18 years. Let us tell you that the SEC has given its approval on the basis of data of Phase II and III trials conducted by Bharat Biotech. However, it is yet to get the approval of DCGI (Drug Controller General of India). Only then can it be included in the national vaccination campaign.

Indigenous Vaccine of Zydus Cadila

Earlier, Zydus Cadila’s indigenous vaccine Zycov-D has been approved in India for children aged 12 to 18 years. However, the production capacity of Zydus Cadila’s Jaycov-D is currently 100 million doses per annum. For this reason, it is believed that this will not speed up the vaccination of children. There is also a reason that three doses have to be given. In such a situation, it will take a lot of time to vaccinate about 14 crore children of the country. It is given into the skin rather than into the muscle. This is the reason why it is taking time to make arrangements for this across the country.

That’s why Covaxin is a better option

This is the reason why Covaccin is being considered a better option for this. If it gets the final approval, then this will give impetus to vaccination. At the same time, the states also have its stock. In such a situation, it will be possible to reserve it for children. Bharat Biotech is hopeful that it will get approval soon. With the approval, vaccination of children will be started on a large scale.

their ongoing trial

Apart from these, two more vaccine trials are going on for children in India, one is Serum Institute’s Kovavax and the other is Biological E’s Corbevax. Kovavax has received permission from DCGI for trials on children aged 7-11 years. At the same time, Corbevax has already been given permission for trials for children above five years of age.

condition of the countries of the world

Cuba has allowed children over the age of two, China, Chile to allow children over the age of six, the UAE to children over the age of three, and the United States to children over the age of six in El Salvador. The vaccine has been approved for older children. The vaccine has been approved for children over the age of 12 in France, Denmark, Germany, Italy, Ireland, Spain, Switzerland, Sweden, Canada and Poland. China is giving Sinovac and CoronaVac vaccines here, while China’s Sinovac vaccine is also being installed in Chile. At the same time, the European Medicines Agency (EMA) has approved the use of Pfizer and BioNTech vaccines for children over the age of 12.

Edited By: Kamal Verma